Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis

ObjectivePyrotinib and pertuzumab are effective treatment options for HER2-positive metastatic breast cancer (HER2+ MBC). Our study was to directly compare the efficacy and safety of pyrotinib plus trastuzumab (PyroH) and pertuzumab plus trastuzumab (HP) in patients with HER2+ MBC.MethodsWe conducte...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Shuhui You, Yizhao Xie, Die Sang, Ting Luo, Peng Yuan, Fei Xu, Biyun Wang
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2023-12-01
Saila:	Frontiers in Endocrinology
Gaiak:	human epidermal growth factor receptor 2 (HER2) metastatic breast cancer (MBC) pyrotinib trastuzumab pertuzumab
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1325540/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!